Expression of human VEGF(121) cDNA in mouse bone marrow stromal cells / 中华医学杂志(英文版)
Chin. med. j
; Chin. med. j;(24): 914-918, 2002.
Article
de En
| WPRIM
| ID: wpr-302275
Bibliothèque responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To construct a retroviral vector carrying human vascular endothelial growth factor (hVEGF (121)) cDNA for evaluation of the possibility of VEGF gene therapy in ischemic bone disease.</p><p><b>METHODS</b>hVEGF(121) cDNA was obtained from the plasmid pCDI/VEGF(121) and cloned into retroviral plasmid pLXSN. Recombinant plasmid was transferred to the retro virus packaging cell, PT-67, by lipofectamine mediated gene transfer. Mouse bone marrow stromal cells (MSCs) were transfected by the retrovirus. The integration of the hVEGF(121) cDNA into MSC genomic DNA and expression of the VEGF gene was detected. Proliferation assays of human umbilical vein endothelial cells (HUVECs) by VEGF(121) in culture medium were performed.</p><p><b>RESULTS</b>Recombinant pLXSN/VEGF(121) was correctly constructed and confirmed by restriction endonuclease analysis and DNA sequencing analysis. hVEGF(121) gene was integrated into MSC genomic DNA after transfection, and the VEGF(121) protein was expressed. Proliferation assays showed VEGF(121) in culture medium was a biologically active protein and had a mitogenic effect on HUVEC.</p><p><b>CONCLUSIONS</b>Recombinant retroviral vector carrying hVEGF(121) cDNA was successfully constructed. VEGF (121) protein expressed by MSCs had mitogenic effect biologically. This provides a further foundation for VEGF gene therapy for bone ischemic disease and bone tissue engineering.</p>
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Plasmides
/
Retroviridae
/
Cellules de la moelle osseuse
/
Endothélium vasculaire
/
Thérapie génétique
/
Division cellulaire
/
Facteurs de croissance endothéliale
/
Lymphokines
/
Cellules stromales
/
ADN complémentaire
Limites du sujet:
Animals
/
Humans
langue:
En
Texte intégral:
Chin. med. j
Année:
2002
Type:
Article